WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2006086727) TREATING DIABETES WITH GLUCAGON-LIKE PEPTIDE-1 SECRETAGOGUES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2006/086727    International Application No.:    PCT/US2006/004922
Publication Date: 17.08.2006 International Filing Date: 09.02.2006
IPC:
A61K 31/155 (2006.01), A61K 31/444 (2006.01), A61P 3/10 (2006.01)
Applicants: ENTELOS, INC. [US/US]; 110 Marsh Drive, Foster City, California 94404 (US) (For All Designated States Except US).
POLIDORI, David [US/US]; (US) (For US Only).
SILER, Scott [US/US]; (US) (For US Only)
Inventors: POLIDORI, David; (US).
SILER, Scott; (US)
Agent: OFFICES OF KAREN E. FLICK; P.O.Box 515, El Granada, CA 94018-0515 (US)
Priority Data:
60/651,739 09.02.2005 US
Title (EN) TREATING DIABETES WITH GLUCAGON-LIKE PEPTIDE-1 SECRETAGOGUES
(FR) TRAITEMENT DES DIABETES AU MOYEN DE SECRETAGOGUES DU GLUCAGON-LIKE PEPTIDE 1
Abstract: front page image
(EN)In general this invention can be viewed as encompassing novel methods of treating diabetes and insulin resistance. The inventors have made the discovery that increasing secretion of endogenous glucagon-like peptide-1 (GLP-1) in combination with inhibiting the activity of dipeptidyl peptidase I (DPP-IV) can have a significant impact on hyperglycemia and insulin secretion in subjects suffering from diabetes and/or insulin resistance. Further the invention encompasses methods of identifying subjects having elevated secretion of GLP-1, methods of assessing sensitivity to a GLP-1 secretagogue, and methods of treating diabetes in these subjects by administering a GLP-1 secretagogue to alleviate at least one symptom of diabetes.
(FR)L'invention concerne, d'une manière générale, des méthodes de traitement des diabètes et de la résistance à l'insuline. Les inventeurs ont découvert que la sécrétion accrue du glucagon-like peptide-1 (GLP-1) endogène conjointement avec l'inhibition de l'activité de la dipeptidyl peptidase I (DPP-IV) peut avoir un impact important sur l'hyperglycémie et la sécrétion de l'insuline chez des sujets souffrant de diabètes et/ou de la résistance à l'insuline. De plus, l'invention concerne des procédés d'identification de sujets présentant une sécrétion élevée de GLP-1, des procédés d'évaluation de la sensibilité à un sécrétagogue GLP-1 et des méthodes de traitement de diabètes chez ces sujets consistant à administrer un sécrétagogue GLP-1, afin de soulager au moins un symptôme des diabètes.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)